Dr. Kacey Broadhurst, PSYD Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 20 Library St, Hudson, NH 03051 Phone: 603-881-3930 |
News Archive
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.
Tomsk Polytechnic University, JSC Academician M.F. Reshetnev Information Satellite Systems and the Polyus Research and Development Center will create the betatron based medical complexes, reducing the chance of cancer recurrence.
IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.
Despite the fact that the majority of women presenting to emergency departments for care after sexual assault experience severe pain, very few receive pain treatment. These were the findings of a multi-site research study led by Samuel McLean, MD, MPH, director of the TRYUMPH Research Program in the Department of Anesthesiology at the University of North Carolina School of Medicine. The results were published online in the Journal of Pain on June 15, 2012.
› Verified 8 days ago